Iovance shares plunge after new phase 2 Amtagvi data in lung cancer
Iovance shares dropped sharply after new phase 2 results for Amtagvi in non-small-cell lung cancer, per Seeking Alpha. Few details were given in the report.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Shares of Iovance Therapeutics fell sharply after new phase 2 data on Amtagvi in non-small-cell lung cancer were released, according to Seeking Alpha.
The report offers no further figures on the drug's efficacy or safety, so the reasons behind the market reaction cannot be judged from the available information.
why it matters
The sharp drop shows how investors are weighing fresh clinical results for the drug in a new indication. For companies at an early stage of commercialization, such releases often become the main driver of the share price.
market impact
Iovance shares: negative market reaction to trial data puts pressure on the stock.
- Iovance shares pressure down — new phase 2 data for the drug triggered a sharp selloff
tags
instruments
sources
- Iovance plummets on new phase 2 Amtagvi data for non-small-cell lung cancer — Seeking Alpha, 29 October 2026 at 19:11 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗